198 related articles for article (PubMed ID: 25938292)
1. Health-related quality of life in patients with alpha-1 antitrypsin deficiency: the French experience.
Gauvain C; Mornex JF; Pison C; Cuvelier A; Balduyck M; Pujazon MC; Fournier M; AitIlalne B; Thabut G
COPD; 2015 May; 12 Suppl 1():46-51. PubMed ID: 25938292
[TBL] [Abstract][Full Text] [Related]
2. Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Int J Chron Obstruct Pulmon Dis; 2017; 12():1427-1437. PubMed ID: 28553095
[TBL] [Abstract][Full Text] [Related]
3. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV
Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R
Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839
[TBL] [Abstract][Full Text] [Related]
4. The impact of smoke exposure on the clinical phenotype of alpha-1 antitrypsin deficiency in Ireland: exploiting a national registry to understand a rare disease.
O'Brien ME; Pennycooke K; Carroll TP; Shum J; Fee LT; O'Connor C; Logan PM; Reeves EP; McElvaney NG
COPD; 2015 May; 12 Suppl 1():2-9. PubMed ID: 25938284
[TBL] [Abstract][Full Text] [Related]
5. Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT).
Esquinas C; Serreri S; Barrecheguren M; Rodriguez E; Nuñez A; Casas-Maldonado F; Blanco I; Pirina P; Lara B; Miravitlles M
Int J Chron Obstruct Pulmon Dis; 2018; 13():1001-1007. PubMed ID: 29615836
[TBL] [Abstract][Full Text] [Related]
6. Decline in FEV
Hiller AM; Piitulainen E; Jehpsson L; Tanash H
Int J Chron Obstruct Pulmon Dis; 2019; 14():1075-1083. PubMed ID: 31213789
[No Abstract] [Full Text] [Related]
7. Usefulness of the CAT, LCOPD, EQ-5D and COPDSS scales in understanding the impact of lung disease in patients with alpha-1 antitrypsin deficiency.
Manca S; Rodriguez E; Huerta A; Torres M; Lazaro L; Curi S; Pirina P; Miravitlles M
COPD; 2014 Sep; 11(5):480-8. PubMed ID: 24832005
[TBL] [Abstract][Full Text] [Related]
8. The cross-sectional and longitudinal association of the BODE index with quality of life in patients with chronic obstructive pulmonary disease.
Lin YX; Xu WN; Liang LR; Pang BS; Nie XH; Zhang J; Wang H; Liu YX; Wang DQ; Xu ZY; Wang HW; Zhang HS; He ZY; Yang T; Wang C
Chin Med J (Engl); 2009 Dec; 122(24):2939-44. PubMed ID: 20137478
[TBL] [Abstract][Full Text] [Related]
9. Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Respir Med; 2017 Sep; 130():1-8. PubMed ID: 29206626
[TBL] [Abstract][Full Text] [Related]
10. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?
Stockley RA; Edgar RG; Pillai A; Turner AM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1745-56. PubMed ID: 27536086
[TBL] [Abstract][Full Text] [Related]
11. Maximal mid-expiratory flow detects early lung disease in α
Stockley JA; Ismail AM; Hughes SM; Edgar R; Stockley RA; Sapey E
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28356373
[TBL] [Abstract][Full Text] [Related]
12. Spanish Registry of Patients With Alpha-1 Antitrypsin Deficiency; Comparison of the Characteristics of PISZ and PIZZ Individuals.
Lara B; Miravitlles M
COPD; 2015 May; 12 Suppl 1():27-31. PubMed ID: 25938288
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary
Lessard E; Young HM; Bhalla A; Pike D; Sheikh K; McCormack DG; Ouriadov A; Parraga G
Acad Radiol; 2017 Nov; 24(11):1402-1411. PubMed ID: 28645458
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of Alpha-1 Antitrypsin-Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease.
Stoller JK; Aboussouan LS; Kanner RE; Wilson LA; Diaz P; Wise R;
Ann Am Thorac Soc; 2015 Dec; 12(12):1796-804. PubMed ID: 26653189
[TBL] [Abstract][Full Text] [Related]
15. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM
Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314
[TBL] [Abstract][Full Text] [Related]
16. Impact of comorbidities on COPD-specific health-related quality of life.
Burgel PR; Escamilla R; Perez T; Carré P; Caillaud D; Chanez P; Pinet C; Jebrak G; Brinchault G; Court-Fortune I; Paillasseur JL; Roche N;
Respir Med; 2013 Feb; 107(2):233-41. PubMed ID: 23098687
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiency.
Omachi TA; Eisner MD; Rames A; Markovtsova L; Blanc PD
Respir Res; 2011 Mar; 12(1):35. PubMed ID: 21429222
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the Spiration Valve System™ for the treatment of severe emphysema in patients with Alpha-1 antitrypsin deficiency (EMPROVE).
Hogarth DK; Delage A; Zgoda MA; Nsiah-Dosu S; Himes D; Reed MF
Respir Med; 2024 Apr; 224():107565. PubMed ID: 38364975
[TBL] [Abstract][Full Text] [Related]
19. [Characteristics of the patients included in the French cohort of patients with emphysema caused by alpha-1 antitrypsin deficiency].
Thabut G; Mornex JF; Cuvelier A; Padrazzi B; Pison C; Neukirch F; Lafitte JJ; Boczkowski J; Balduyck M; Muir JF; Carles P; Fournier M
Rev Mal Respir; 2008 Nov; 25(9):1115-22. PubMed ID: 19106908
[TBL] [Abstract][Full Text] [Related]
20. Long-Term SGRQ Stability in a Cohort of Individuals with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease.
Choate R; Holm KE; Sandhaus RA; Mannino DM; Strange C
Int J Chron Obstruct Pulmon Dis; 2024; 19():889-900. PubMed ID: 38617018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
